The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Real-world outcomes of atezolizumab and durvalumab in extensive-stage SCLC
Apar Ganti, MD, University of Nebraska Medical Center, Omaha, NE presents real-word data of atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer (SCLC). Median overall survival was found to be lower in real-world data than in the trial data, which is in-line with other agents that show poorer real-world outcomes compared with those observed in clinical trials. Prof. Ganti highlights that there does not appear to be any difference between atezolizumab and durvalumab in real-world data. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
